The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Once- and Twice-Daily Dosing With Rosiglitazone Improves Glycemic Control in Patients With Type 2 Diabetes
Abstract
OBJECTIVE— To determine the efficacy of rosiglitazone compared with placebo in reducing hyperglycemia. RESEARCH DESIGN AND METHODS— After a 4-week placebo run-in period, 959 patients were randomized to placebo or rosiglitazone (total daily dose 4 or 8 mg) for 26 weeks. The primary measure of efficacy was change in the HbAlc concentration. RESULTS— Rosiglitazone produced dosage-dependent reductions in HbAlc of 0.8, 0.9, 1.1, and 1.5% in the 4 mg o.d., 2 mg b.i.d., 8 mg o.d., and 4 mg b.i.d. groups, respectively, compared with placebo. Clinically significant decreases from baseline in HbAlc were observed in drug-naive patients at all rosiglitazone doses and in patients previously treated with oral monotherapy at rosiglitazone 8 mg o.d. and 4 mg b.i.d. Clinically significant decreases from baseline in HbAlc were also observed with rosiglitazone 4 mg b.i.d. in patients previously treated with combination oral therapy. Approximately 33% of drug-naive patients treated with rosiglitazone achieved HbAlc ≤7% at study end. The proportions of patients with at least one adverse event were comparable among the rosiglitazone and placebo groups. There was no evidence of hepatotoxicity in any treatment group. There were statistically significant increases in weight and serum lipids in all rosiglitazone treatment groups compared with placebo. For LDL and HDL cholesterol, the observed increase appeared to be dose related. CONCLUSIONS— Rosiglitazone at total daily doses of 4 and 8 mg significantly improved glycemic control in patients with type 2 diabetes and was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance.
National Diabetes Data Group (1979) · Diabetes · doi:10.2337/diab.28.12.1039 · Cited by 4,909
Pathogenesis of NIDDM. A balanced overview.
DeFronzo, R. A., Bonadonna, R. C., & Ferrannini, E. (1992) · Diabetes Care · doi:10.2337/diacare.15.3.318 · Cited by 2,085
Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
Saltiel, A. R., & Olefsky, J. M. (1996) · Diabetes · doi:10.2337/diab.45.12.1661 · Cited by 1,053
Role of Insulin Resistance in Human Disease (Syndrome X): An Expanded Definition
Reaven, G. M. (1993) · Annual Review of Medicine · doi:10.1146/annurev.me.44.020193.001005 · Cited by 912
The homeostasis model in the San Antonio Heart Study.
Haffner, S. M., Miettinen, H., & Stern, M. P. (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1087 · Cited by 788
Fonseca, V., Rosenstock, J., Patwardhan, R., & Salzman, A. (2000) · JAMA · doi:10.1001/jama.283.13.1695 · Cited by 540
Self-citationCholesterol and Coronary Heart Disease: Predicting Risks by Levels and Ratios
Kinosian, B., Glick, H., & Garland, G. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-9-199411010-00002 · Cited by 519
Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes
Lebovitz, H. E., Dole, J., Patwardhan, R., Rappaport, E. B., & Freed, M. I. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.1.280 · Cited by 518
Self-citationEmoto, M., Nishizawa, Y., Maekawa, K., Hiura, Y., Kanda, H., Kawagishi, T., Shoji, T., Okuno, Y., & Morii, H. (1999) · Diabetes Care · doi:10.2337/diacare.22.5.818 · Cited by 457
Thiazolidinediones: a new class of antidiabetic drugs
Day, C. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00023.x · Cited by 436
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00001 · Cited by 385
Pioglitazone Induces In Vivo Adipocyte Differentiation in the Obese Zucker fa/fa Rat
Haliakon, S., Doaré, L., Foufelle, F., Kergoat, M., Guerre-Millo, M., Berthault, M.-F., Dugail, I., Morin, J., Auwerx, J., & Ferré, P. (1997) · Diabetes · doi:10.2337/diab.46.9.1393 · Cited by 306
Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes
Hermans, M. P., Levy, J. C., Morris, R. J., & Turner, R. C. (1999) · Diabetologia · doi:10.1007/s001250051215 · Cited by 260
Young, P. W., Buckle, D. R., Cantello, B. C. C., Chapman, H., Clapham, J. C., Coyle, P. J., Haigh, D., Hindley, R. M., Holder, J. C., Kallender, H., et al. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37268-4 · Cited by 237
Young, P. W., Buckle, D. R., Cantello, B. C. C., Chapman, H., Clapham, J. C., Coyle, P. J., Haigh, D., Hindley, R. M., Holder, J. C., Kallender, H., et al. (1998) · PubMed · Cited by 229
Long-Term Glycemic Control Relates to Mortality in Type II Diabetes
Andersson, D. K., & Svärdsudd, K. (1995) · Diabetes Care · doi:10.2337/diacare.18.12.1534 · Cited by 221
Efficacy of metformin in the treatment of NIDDM. Meta-analysis.
Johansen, K. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.33 · Cited by 186
Piaggesi, A., Schipani, E., Campi, F., Romanelli, M., Baccetti, F., Arvia, C., & Navalesi, R. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199805)15:5<360::aid-dia568>3.0.co;2-w · Cited by 182
Epidemiologic aspects of lipid abnormalities
Criqui, M. H., & Golomb, B. A. (1998) · The American Journal of Medicine · doi:10.1016/s0002-9343(98)00212-5 · Cited by 158
Troglitazone Reduces Plasma Leptin Concentration but Increases Hunger in NIDDM Patients
Shimizu, H., Tsuchiya, T., Sato, N., Shimomura, Y., Kobayashi, I., & Mori, M. (1998) · Diabetes Care · doi:10.2337/diacare.21.9.1470 · Cited by 115
The synthesis of BRL 49653 - a novel and potent antihyperglycaemic agent
Cantello, B. C. C., Cawthorne, M. A., Haigh, D., Hindley, R. M., Smith, S. A., & Thurlby, P. L. (1994) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(01)80325-5 · Cited by 112
Fukushima, M., Taniguchi, A., Sakai, M., Doi, K., Nagasaka, S., Tanaka, H., Tokuyama, K., & Nakai, Y. (1999) · Diabetes Care · doi:10.2337/diacare.22.11.1911 · Cited by 73
Overweight: Fat Distribution and Health Risks. Epidemiological Observations
Seidell, J. C., HAUTVAST, J. G. A. J., & Deurenberg, P. (1989) · Transfusion Medicine and Hemotherapy · doi:10.1159/000222401 · Cited by 43
Troglitazone has no effect on red cell mass or other erythropoietic parameters
Young, M. M. R., Squassante, L., Wemer, J., van Marle, S. P., Dogterom, P., & Jonkman, J. H. G. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050602 · Cited by 33
Cited by
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Goldberg, R. B., Kendall, D. M., Deeg, M. A., Buse, J. B., Zagar, A. J., Pinaire, J. A., Tan, M. H., Khan, M. A., Perez, A. T., Jacober, S. J., et al. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1547 · Cited by 795
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1002/hep.1840380427 · Cited by 751
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 594
Metadata
- Authors
- Phillips, L. S., Grunberger, G., Miller, E., Patwardhan, R., Rappaport, E. B., Salzman, A., & the Rosiglitazone Clinical Trials Study Group
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2001-02-01
- Volume
- 24
- Issue
- 2
- Pages
- 308-315
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2131669718
- Cited by
- 302
- References
- 28
- FWCI
- 23.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.